Sort By

JAK2 Monoclonal Antibody (691R5) (Invitrogen™)

JAK2 Monoclonal Antibody for Western Blot

JAK2 (Phospho) [pY1007/pY1008] Human ELISA Kit (Invitrogen™)

JAK2 (Phospho) [pY1007/pY1008] Human ELISA Kit for ELISA

Phospho-JAK2 (Tyr1007, Tyr1008) Recombinant Polyclonal Antibody (18HCLC) (Invitrogen™)

Phospho-JAK2 (Tyr1007, Tyr1008) Recombinant Polyclonal Antibody for Western Blot, IF, ICC

LanthaScreen™ STAT5 (JAK2 V617F) U2OS Cell Line

LanthaScreen® GFP Cellular Assays allow for the analysis of post-translational modifications for a number of target proteins in an live-cell context. The JAK2⁄STAT5 signaling pathway plays an essential role in blood cell formation in response to cytokines such as GM-CSF, IL-3, and EPO. The recent discovery of an activating mutation in JAK2 (V617F) present in high percentage of myeloproliferative disease (MPD) patients suggests that this mutant JAK2 activity is a potential therapeutic target for certain forms of MPD. The assay described in this summary makes use of a cell line engineered for expression of the constitutively-active mutant kinase JAK2 V617F. By co-expressing GFP-STAT5 in this background, the phosphorylation state of STAT5 (specifically residue Tyr 694⁄699) can be modulated with JAK2 V617F inhibitors and analyzed in cell lysates using an anti-STAT5 [pTyr 694⁄699] and LanthaScreenTM terbium-anti-mouse antibody pair. GFP-STAT5 Lentivirus was transduced into U2OS cells followed by selection with Blasticidin. The selected pool was then transfected with a GST-JAK2 V617F construct using LipofectamineTM LTX, followed by selection with Geneticin. This cell line is a clonal population isolated by flow cytometry using GFP fluorescence as sorting marker, and has been screened for the constitutive expression of GFP-STAT5 and GST-JAK2 V617F. Using a lytic TR-FRET immuno-assay, this cell line is validated for IC50 and Z' under optimized conditions using JAK Inhibitor I (Pyridone 6) as a small molecule inhibitor for JAK2 V617F-mediated GFP-STAT5 phosphorylation. This assay has also been tested for assay performance under variable experimental conditions, including cell plating density, stimulation time, DMSO tolerance and lysis⁄equilibration time.

JAK2 [V617F] Recombinant Human Protein, JH1 and JH2 Domains

JAK2 is a protein tyrosine kinase involved in a specific subset of cytokine receptor signaling pathways. This kinase contains both the JH1 (catalytic) and JH2 (pseudokinase) domains of JAK2. The V617F mutation has been shown to be a cause of polycythemia vera.

JAK2 Recombinant Human Protein, JH1 and JH2 Domains

JAK2 is a protein tyrosine kinase involved in a specific subset of cytokine receptor signaling pathways and is mutated in polycythemia vera. This kinase contains both the JH1 (catalytic) and JH2 (pseudokinase) domains of JAK2.

JAK2 Recombinant Rabbit Monoclonal Antibody (18H11L8) (Invitrogen™)

JAK2 Recombinant Monoclonal Antibody for Western Blot, IF, ICC

JAK2 Polyclonal Antibody (Invitrogen™)

JAK2 Polyclonal Antibody for Western Blot

JAK2 (Total) Human ELISA Kit (Invitrogen™)

JAK2 (Total) Human ELISA Kit for ELISA

JAK2 Recombinant Human Protein

Janus kinase 2 (JAK2) is a protein tyrosine kinase involved in a specific subset of cytokine receptor signaling pathways and is mutated in polycythemia vera. This kinase contains the catalytic domain (JH1) of JAK2.

Phospho-JAK2 (Tyr1007, Tyr1008) Polyclonal Antibody (Invitrogen™)

Phospho-JAK2 (Tyr1007, Tyr1008) Polyclonal Antibody for Western Blot

Phospho-JAK2 (Tyr1007, Tyr1008) Recombinant Rabbit Monoclonal Antibody (18H13L8) (Invitrogen™)

Phospho-JAK2 (Tyr1007, Tyr1008) Recombinant Monoclonal Antibody for Western Blot

Phospho-JAK2 (Tyr119) Polyclonal Antibody (Invitrogen™)

Phospho-JAK2 (Tyr119) Polyclonal Antibody for Western Blot

Phospho-JAK2/JAK3 (Tyr966, Tyr939) Polyclonal Antibody (Invitrogen™)

Phospho-JAK2/JAK3 (Tyr966, Tyr939) Polyclonal Antibody for Western Blot

Phospho-JAK2/JAK3 (Tyr966, Tyr939) Polyclonal Antibody (Invitrogen™)

Phospho-JAK2/JAK3 (Tyr966, Tyr939) Polyclonal Antibody for Western Blot